NCT06347068

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

RecruitingPHASE1INTERVENTIONAL

Trial Details

Start: 2024-06-27Est. Completion: 2028-05-22

Enrollment target: 42 participants

Locations

University of North Carolina, Chapel Hill, North Carolina, United States

Contact

Caroline BabinecUNCImmunotherapy@med.unc.edu 919-445-4208

Catherine ChengUNCImmunotherapy@med.unc.edu +1 919-445-4208

Other microbiome trials you might be interested in

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid TumorsPhase 1Recruiting

Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Non-small Cell Lung Cancer (NSCLC)HR+/HER2- Ductal Breast Cancer (BC)HR+/HER2- Lobular Breast Cancer (BC)Triple Negative Breast Cancer (TNBC)Colorectal Cancer (CRC)Soft Tissue Sarcoma (STS)

The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokine…

Chuo Ku, JapanEst. completion Jan 16, 2028

View Trial →

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)Phase 1Recruiting

HER2 Expressing Solid Tumors

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.